Jamile Shammo
Overview
Explore the profile of Jamile Shammo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi J, Ozcan Y, Santos C, Patel H, Shammo J, Bat T
Ther Adv Hematol
. 2024 Dec;
15:20406207241307500.
PMID: 39734592
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder which is caused by mutations in phosphatidylinositol glycan class A leading to hemolysis of red blood cells via complement inhibition. The...
2.
Kulasekararaj A, Kulasekararaj A, Griffin M, Piatek C, Piatek C, Shammo J, et al.
Blood
. 2024 Dec;
145(8):811-822.
PMID: 39700502
Complement C5 inhibitor treatment with ravulizumab or eculizumab for paroxysmal nocturnal hemoglobinuria (PNH) improves outcomes and survival. Some patients remain anemic due to clinically significant extravascular hemolysis (cs-EVH; hemoglobin [Hb]...
3.
Dingli D, De Castro Iii C, Koprivnikar J, Kulasekararaj A, Maciejewski J, Mulherin B, et al.
Hematology
. 2024 Dec;
29(1):2329030.
PMID: 39665683
Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, non-malignant hematologic disease characterized by complement-mediated hemolysis (with or without hemoglobinuria), fatigue, increased susceptibility to thrombosis, and bone marrow dysfunction. The...
4.
Waheed A, Shammo J, Dingli D
Blood Rev
. 2023 Dec;
64:101158.
PMID: 38071133
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder caused by complement-mediated hemolysis and thrombosis through the alternative pathway. The most common symptom of PNH is fatigue due to chronic anemia,...
5.
Shammo J, Gajra A, Patel Y, Tomazos I, Kish J, Hill A, et al.
J Blood Med
. 2022 Aug;
13:425-437.
PMID: 35983240
Purpose: Most patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with a complement protein 5 (C5) inhibitor achieve full control of terminal complement activity and intravascular hemolysis. The minority remains anemic...
6.
Cavazos K, Eswaran S, Maidlow C, Keklik Karadag F, Idilman R, Idilman I, et al.
Blood Adv
. 2022 Jul;
6(20):5630-5633.
PMID: 35839085
No abstract available.
7.
Daly R, Jalbert J, Keith S, Symonds T, Shammo J
J Patient Rep Outcomes
. 2021 Sep;
5(1):102.
PMID: 34581910
Background: Patient-reported outcome measures (PROs) used to measure symptoms of patients with paroxysmal nocturnal hemoglobinuria (PNH) in trials do not measure PNH symptoms comprehensively and do not assess daily fluctuations...
8.
Nathan S, Bharadwaj S, Luke K, Kalas L, Katz D, Junaid Hussain M, et al.
Leuk Lymphoma
. 2020 Apr;
61(8):2008-2011.
PMID: 32306813
No abstract available.
9.
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
Ronner L, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, OConnell C, et al.
Blood
. 2020 Feb;
135(19):1696-1703.
PMID: 32107559
There are unresolved questions regarding the association between persistent leukocytosis and risk of thrombosis and disease evolution in polycythemia vera (PV), as much of the published literature on the topic...
10.
Elliott E, Waheed S, Syed S, Eswaran S, Gregory S, Shammo J
Clin Lymphoma Myeloma Leuk
. 2017 Nov;
18(1):e9-e12.
PMID: 29102415
No abstract available.